OpenAlex
PricingAboutJobs
Log inGet started
Work

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

HTML

Year: 2007
Type: article
Study design: Observational Study
Source: Blood
DOI: 10.1182/blood-2007-06-093617
Authors: Deborah L. White, Verity A. Saunders, Phuong Dang, Jane Engler, Amity Venables, Stephanie Zrim, Andrew Zannettino, Kevin Lynch, Paul W. Manley, Timothy Hughes
Institutions: South Australia Pathology, Hanson Institute, The University of Adelaide, Novartis (Australia), Novartis (Switzerland), Novartis Institutes for BioMedical Research, Royal Adelaide Hospital
Language: English

Topic: Chronic Myeloid Leukemia Treatments
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: chronic myeloid leukemia, imatinib, Oct-1, OCT1, drug response variability, major molecular response, predictive biomarkers
SDG: Good health and well-being

Open Access status: closed

Funders: National Health and Medical Research Council, National Medical Research Council
OpenAlex ID: W2074740555
FWCI: 24.21
Cites: 29
Cited by: 365
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms